ageas SA/NV Overview
Ageas is a Brussels-based international insurance group with roughly 200 years of heritage. It combines wholly owned European insurers with long-term bank and distributor partnerships in Asia. Since April 2026 it owns 100% of AG Insurance, Belgium's market leader, with about 28% Life and 17% Non-Life market share (Ageas corporate presentation, 8 Oct 2026). The September 2025 esure acquisition made it a top-three UK personal-lines insurer. It holds leading partnership positions in China (Taiping), India, Thailand, Vietnam and Türkiye, and has built Ageas Re into a fourth growth segment since 2023. Gross inflows reached EUR 19.6bn in FY2025 and Net Operating Result EUR 1.65bn (EUR 1.35bn excluding a one-off China tax benefit). Management has spent 2025–26 reshaping the portfolio: buying control in Belgium and scale in the UK, and exiting Malaysia at about 2x book. The aim is to raise the share of cash-generating, consolidated earnings under the Elevate27 plan (2025–27).
What the company does. Ageas is an insurance holding company. Through subsidiaries, joint ventures and associates, it underwrites Life insurance and Non-Life (property & casualty, health, accident) insurance, and has written third-party reinsurance since 2023. The Life side covers guaranteed savings, unit-linked investment products, protection, pensions and employee benefits. The group also manages large investment portfolios backing ~EUR 117bn of Life liabilities (H1 2026 press release). Through AG Insurance it owns AG Real Estate, a major Belgian property investor and developer.
Business model. The group runs a "hybrid" model:
-
Consolidated, wholly owned operations in Belgium (AG Insurance, 100% since 28 Apr 2026), the UK (Ageas UK, esure, Acromas/AICL) and Portugal. These produce the bulk of the cash upstream to the holding.
-
Non-consolidated partnerships — equity-accounted JVs and associates — with banks and conglomerates in China (China Taiping), India (Federal Bank, Sundaram Finance), Thailand (Muang Thai), Vietnam, the Philippines, Laos, Cambodia and Türkiye (Sabancı). Ageas contributes technical, actuarial and product know-how. The partners contribute distribution, chiefly bancassurance and agency networks.
-
Ageas Re, launched for third-party business in 2023. It writes inward reinsurance and also centralises internal reinsurance, including a quota share programme on Belgian business (the 2025 Belgian combined ratio of 90.5% is quoted "before the quota share reinsurance programme" — Ageas corporate presentation, 8 Oct 2026).
Revenue model. As an insurer, Ageas does not sell products, services, subscriptions or licences in the industrial sense. Its economic revenue has three parts:
-
Insurance service revenue: premiums earned, recognised under IFRS 17 as the Contractual Service Margin (CSM) is released.
-
Investment income on the general account.
-
Fee margins on unit-linked and pension assets.
Gross inflows in FY2025 were EUR 19.6bn. On the FY2024 split, Life was EUR 11.7bn (~63%) and Non-Life EUR 6.8bn (~37%) (Ageas FY2024 press release). The CSM, the stock of unearned future Life profit, stood at EUR 11.1bn at H1 2026.
Value-chain position. Ageas sits in primary underwriting and risk carrying, and in asset-liability management. Distribution is largely outsourced or partnered:
-
Belgium: independent brokers (AG's broker channel) plus exclusive bancassurance with BNP Paribas Fortis, renewed for 15 years from 1 Jan 2027.
-
UK: brokers, price comparison websites (PCW), direct (esure), affinity (Saga, a 20-year agreement) and embedded partners (BYD, Wrisk).
-
Asia: bank branches and agents (Taiping Life: ~230,000 agents and access to ~70,000 bank branches).
Asset management is partly internal, and since 2026 partly through a long-term partnership between AG Insurance and BNP Paribas Asset Management.
Customer types and end-markets. The group serves:
-
Retail individuals (motor, home, savings, protection, health).
-
Older and retired customers (the "ageing" strategic focus and the Saga over-50s franchise).
-
SMEs (an Elevate27 growth priority).
-
Corporates and employers (group pensions and employee benefits in Belgium; Taiping Pension in China).
-
Cedents, i.e. other insurers buying reinsurance (Ageas Re).
Company self-description (paraphrased from FY2025 releases). Ageas describes itself as a Belgian-rooted, listed international insurance group with a 200-year heritage. It concentrates on Europe and Asia, which together make up most of the global insurance market, and ranks among the market leaders in each country where it operates. It serves retail and business customers in Life and Non-Life through wholly owned subsidiaries and long-term partnerships with strong financial institutions and distributors (Ageas boilerplate, press releases 2025–26).
Independent characterisation. Ageas is best seen as a Belgian life-and-P&C champion with a cash-generative core, attached to a portfolio of minority Asian growth options and a now-scaled UK personal-lines franchise. Its earnings mix is unusual among EU mid-cap insurers. Asia contributed EUR 860m of FY2025 NOR, about 48% of segment NOR before General Account costs, inflated by a EUR 300m one-off China deferred-tax benefit. Yet Asia remits relatively little cash: MAHB, for example, remitted EUR 21m against EUR 64m NOR in 2025. Management's 2025–26 actions — 100% of AG, esure, the Saga affinity deal, and selling Malaysia at about 2x book — shift the mix toward consolidated, remittable earnings. That supports the progressive dividend (DPS +6% p.a. targeted) while keeping a China growth anchor through Taiping. The main analytical tensions are three: the quality and fungibility of Asian earnings, the integration risk of esure, and the strategic implications of BNP Paribas's 24.1% stake.
Strategy
Elevate27 (2025–2027) — stated themes
Elevate27 succeeded Impact24 (2022–24) and Connect21 (2019–21). The company frames it around three strategic choices:
-
profitable growth;
-
technical insurance and operational excellence;
-
distribution excellence and customer experience.
Sustainability is described as "at the core" (Ageas corporate presentation, 8 Oct 2026; Ageas sustainability page).
Named growth priorities: solutions for an ageing society (longevity, decumulation, health); SME; retail P&C; reinsurance; and a more locally driven Health & Protection approach. The group's diversification logic has three parts:
-
expand consolidated, cash-generating entities in Europe;
-
sustain a strong presence in growing Asian markets;
-
establish Reinsurance as an overarching business (CEO, FY2025 release).
Financial targets and evolution
| Target (2025–27 cycle) | At launch (Dec 2024) | After H1 2025 (Aug 2025) | Latest (Oct 2026) |
|---|---|---|---|
| Average NOR EPS growth (% p.a.) | 6–8 | 6–8 | 6–8 |
| 2027 EPS (EUR) | — | — | 8.00–8.50, upper end expected |
| Holding Free Cash Flow, cumulative (EUR bn) | >2.2 | >2.3 | >2.6 |
| Shareholder remuneration, cumulative (EUR bn) | — | >2.0 | >2.2 |
| DPS growth (% p.a.) | 6 | 6 | 6 (progressive) |
| Discounted combined ratio by 2027 (%) | — | — | ~92, excluding exceptional weather |
| Additional Life & Pension liabilities from longevity initiatives by 2027 (EUR bn) | — | — | >2, on track to exceed |
| UK (esure) cost synergies (GBP M p.a.) | >100 (Apr 2025) | >100 | >130 |
Sources: H1 2025 press release; FY2025 press release; Quartr summaries of the 8 Oct 2026 investor update and corporate presentation.
EPS bridge (Investor update, Oct 2026): 4–6% from business growth, 2–3% from margin expansion and 0–1% from capital redeployment, summing to the 6–8% target range.
Initiatives announced in the last 24 months (Oct 2024 – Oct 2026)
| Initiative | Date | Description | Targets / status |
|---|---|---|---|
| Saga partnership + AICL | Oct–Dec 2024; AICL closed 2025 | 20-year exclusive motor/home affinity for over-50s | Go-live targeted Q4 2025 |
| esure acquisition and integration | Apr 2025 – 2027 | Creates a top-3 UK personal-lines insurer | ROI >12%; HFCF/share ~10% accretive after 2027; full financial contribution from 2028 |
| Full ownership of AG Insurance | Dec 2025 – Apr 2026 | EUR 1.9bn; bancassurance renewed to 2041; asset management partnership with BNP Paribas AM | Accretive to Elevate27 targets |
| Taiping Pension stake | May 2024 – Mar 2026 | Entry into China's private pension market | Option to 24.99% within 3 years |
| Exit from MAHB (Malaysia) | Aug–Sep 2026 | Value crystallisation at ~2x book | EUR 464m gain; proceeds "added to firepower" for Europe or Asia |
| Data & AI programme | 2025–26 | >300 use cases deployed; ~40 shareable group-wide; 35% claims/fraud, 20% underwriting, 20% CX | Ongoing |
| Nearly-retired / longevity programme | 2025–26 | Retain maturing Belgian Life liabilities | >EUR 100m retained |
| UK embedded insurance (BYD, Wrisk) | 2025–26 | Point-of-sale motor insurance | Live |
| Ageas Federal Life digital distribution | May 2026 | Aggregator partnership | 3x premium by FY28 ambition |
Sustainability commitments (Elevate27)
There are five non-financial KPIs: ESG ratings, sustainable products, customer cNPS, employee eNPS and gender diversity.
-
ESG rating target: top quartile with 3 of the 5 agencies the group engages with.
-
2025 eNPS was 45.8 (top quartile).
-
13 entities benchmark cNPS (Ageas newsroom, 2026).
Guidance
| Item | Guidance | Date |
|---|---|---|
| FY2026 NOR | >EUR 1.95bn, incl. ~EUR 450m MAHB gain, ~EUR 30m lost contribution, and an assumed ~3pp weather impact on the combined ratio | 27 Aug 2026 |
| FY2026 cash upstream | >EUR 1.4bn (+49%) | 27 Aug 2026 |
| FY2026 interim DPS | EUR 1.50, paid December 2026 | 27 Aug 2026 |
Products & Services
Pricing models for insurance products are risk-based premiums. Product-level pricing is not publicly disclosed and is therefore omitted from each entry.
Belgium — AG Insurance (100%)
| Product line / brand | Description & capabilities | Target customer | Distribution | Notes |
|---|---|---|---|---|
| Guaranteed Life savings ("Branch 21") | Capital-guaranteed savings with guaranteed rate plus profit sharing; underpins the Belgian Life guaranteed margin (102 bps in FY2025) | Retail savers | Brokers; BNP Paribas Fortis bank branches | Core of Belgian Life inflows; Belgian Life growth exceeded 10% in H1 2025 |
| Unit-linked investment insurance ("Branch 23") | Market-linked investment insurance; fee-based margin | Retail and affluent investors | Bancassurance, brokers | Asset management partly via BNP Paribas AM from 2026 |
| Group pensions & employee benefits | Occupational pensions, group life, disability, hospitalisation | Employers, corporates, SMEs | Brokers, direct corporate sales | AG is a market leader in Belgian employee benefits (per company positioning) |
| Health / hospitalisation | Individual and group medical expense cover | Employees, individuals | Brokers, bancassurance | Part of the "locally driven Health & Protection approach" (Elevate27) |
| Retail Non-Life | Motor, fire/home, family liability, legal assistance | Households | Brokers, BNP Paribas Fortis | FY2025 Belgian Non-Life inflows +5% |
| SME / commercial Non-Life | Property, liability, workers' compensation | SMEs | Brokers | Named Elevate27 growth priority |
| "Nearly-retired" / longevity solutions | Retention and decumulation propositions for maturing contracts | 55+ clients | Bancassurance, brokers | >EUR 100m of maturing liabilities retained via the programme (Investor update, 8 Oct 2026) |
| AG Real Estate | Real-estate investment, development, property & car-park management | Institutional (internal and third-party) | Direct | Supports the investment result |
Europe — United Kingdom
| Product line / brand | Description | Target customer | Channel | Notes |
|---|---|---|---|---|
| Ageas UK motor | Private car insurance | Retail | Brokers, affinity, PCW | UK top-3 personal lines with esure |
| Ageas UK home | Buildings and contents | Retail | Brokers, affinity | — |
| esure (brand) | Digital-first motor and home insurer | Price-sensitive digital retail | Direct, PCW | Founded 2000; >2.1m policies at acquisition |
| Sheilas' Wheels | Motor/home brand historically targeted at women drivers | Retail | Direct, PCW | Part of esure |
| First Alternative | Specialist motor/home brand | Retail | Direct/PCW | Part of esure |
| Saga (affinity) | Motor and home for over-50s, underwritten via AICL / Ageas under a 20-year agreement; ~1.2–1.4m Saga policies at signing | Over-50s | Saga Services Ltd (broker) | GBP 80m upfront plus contingent payments up to GBP 30m (2026) and up to GBP 30m (2032) |
| Acromas Insurance Company Ltd (AICL) | Gibraltar-registered underwriter, est. 2003 | — | — | Acquired for ~GBP 67m |
| Embedded motor (BYD) | Ageas UK is lead insurer for BYD's embedded insurance proposition in the UK | EV buyers | Point of sale | — |
| Embedded motor (Wrisk) | Embedded motor delivered with Wrisk | OEM/fleet partners | Digital API | — |
Management ambition: combined UK top-line of GBP 3.25bn by 2028 (Insurance Times). Annual cost synergies above GBP 100m, raised to above GBP 130m at the 8 Oct 2026 investor update (Quartr summary).
Europe — Portugal
| Product line / brand | Description | Notes |
|---|---|---|
| Ageas Portugal (Ageas Seguros) | Multi-line Life and Non-Life via agents and brokers | Built on the 2016 AXA Portugal acquisition |
| Médis | Health insurance brand | Brand ownership per company materials |
| Ocidental | Bancassurance with Millennium bcp | — |
| Seguro Directo | Direct motor/home | Not re-verified in this research |
H1 2026 Portugal was hit by adverse weather (storms), as was Belgium.
Europe — Türkiye (JVs with Sabancı)
| Entity | Line | Notes |
|---|---|---|
| AgeSA | Life and private pensions | Excellent FY2025 Life performance in Türkiye drove Europe Life NOR +20% |
| Aksigorta | Non-Life | Hyperinflation accounting affects results |
Asia
| Entity | Country | Ageas stake | Line | Notes |
|---|---|---|---|---|
| Taiping Life | China | 24.9% | Life (agency, bancassurance) | ~230,000 agents, 15m customers, access to 70,000 bank branches (Ageas newsroom, 2026) |
| Taiping Pension (TPP) | China | 10% (completed 24 Mar 2026) | Pensions, employee benefits | Top-5 player; EUR 71bn pension AUM (2023); option to rise to 24.99% within three years (Caixin) |
| Taiping Asset Management | China | 20% | Asset management | Ranked 6th among insurance asset managers, ~EUR 200bn AUM (Ageas) |
| Taiping Reinsurance | Hong Kong/China | 25% | Reinsurance | — |
| Ageas Federal Life | India | 74% | Life (term, annuity, savings) | Targets 3x premium growth by FY28 (CEO Jude Gomes, Business Standard, Dec 2025); digital distribution partnership with an aggregator, May 2026 |
| Royal Sundaram General | India | 40% | Non-Life | With Sundaram Finance |
| Muang Thai Life / Muang Thai Insurance | Thailand | — | Life / Non-Life | Partnership |
| MB Ageas Life | Vietnam | — | Life | Bancassurance with MB Bank |
| Philippines, Laos, Cambodia entities | — | — | Life / Non-Life | Listed by Ageas/Fitch (14 Oct 2026) as markets of operation |
| Etiqa (MAHB) | Malaysia / Singapore | 30.95% → 0% (sold 11 Sep 2026) | Life, Non-Life, Takaful | #1 Non-Life Takaful in Malaysia; exited |
Reinsurance — Ageas Re
| Offering | Description | Notes |
|---|---|---|
| Third-party P&C reinsurance protection | Treaty reinsurance for external cedents | Inflows +52% in 2024 (second year); third-party inflows +49% in H1 2025 |
| Life reinsurance | Inward Life risk | Part of the "overarching" reinsurance strategy |
| Internal reinsurance / quota share | Group quota share on Belgian business | Centralises risk and capital |
CEO of Ageas Re: Joachim Racz, reporting to MD Reinsurance & Investments Emmanuel Van Grimbergen (Reinsurance News, 2024).
Financial Narrative
Comparability warning. FY2021–FY2022 figures are under IFRS 4 (as originally reported). FY2023–FY2025 are under IFRS 17/9. "Revenue" below means gross inflows, the company's top-line KPI.
Income statement / top line
Sources: FY2021 press release (net result EUR 845m, DPS EUR 2.75); FY2022 press release (net result EUR 1,011m incl. EUR 140m RPN(i); inflows EUR 16.4bn; DPS EUR 3.00); FY2024 press release (FY2023/FY2024 inflows, net result, NOR, NOR EPS; DPS 3.50); dividend calendar (FY2023: interim EUR 1.50 Oct 2023 plus final EUR 1.75 Jun 2024 = EUR 3.25); FY2025 press release and 8 Oct 2026 corporate presentation (insurance result EUR 1,761m; EPS EUR 8.80; NOR EUR 1,655m; net result EUR 1,712m; DPS EUR 3.75).
The company's headline per-share KPI is NOR EPS, shown above. FY2025 EPS of EUR 8.80 is +30% YoY including the China one-off (Quartr summary of the 8 Oct 2026 corporate presentation).
Margins. Gross, operating and EBITDA margins are not meaningful for an insurer. A proxy "net margin" (net result / gross inflows) can be computed:
Inflow CAGR. FY2022 to FY2025 inflows rose from EUR 16.4bn to EUR 19.6bn, a 3-year CAGR of ~6.1% in reported terms. At constant FX the company reports +10% (FY2024) and +9% (FY2025).
Commentary.
Top line: Growth accelerated under Impact24 and Elevate27. FY2024 inflows grew +10% at constant FX and scope (excluding the exited French business): Life +9% to EUR 11.7bn and Non-Life +14% to EUR 6.8bn. FY2025 grew +9% at constant FX, with Life sales strong in every region and Ageas Re adding momentum. H1 2026 inflows rose +17% to EUR 12.1bn at constant FX, or +8% at constant scope, inflated by the extra 25% of AG and by esure/Saga.
Profit: NOR rose from EUR 1,166m (FY2023) to EUR 1,240m (FY2024), despite a higher effective tax rate, driven by a 25% rise in the Life insurance result. It then jumped to EUR 1,655m in FY2025. The FY2025 inflection is partly structural (Non-Life NOR +21% to EUR 548m; combined ratio 92.5%) and partly one-off: a ~EUR 300m deferred-tax benefit from a renewed tax basis in China. Underlying growth was ~9%.
2026: H1 2026 NOR was EUR 776m (+6%), with Life at EUR 629m (+17%) offsetting EUR 180m of weather losses. FY2026 guidance is now above EUR 1.95bn. This includes the ~EUR 450m (realised: EUR 464m) MAHB capital gain and a ~EUR 30m lost MAHB contribution, so implied underlying NOR is roughly EUR 1.5bn+. The guidance was raised from "above EUR 1.5bn" given in February 2026.
Dividends: DPS has compounded from EUR 2.75 (FY2021) to EUR 3.75 (FY2025), a ~8.1% CAGR. A EUR 1.50 interim for FY2026 is due in December 2026. The Elevate27 commitment is +6% DPS per annum.
Balance sheet
Sources: FY2021 press release (Solvency II 197%); FY2022 press release (liquid assets EUR 0.6bn; Solvency II 218%); FY2024 press release (liquid assets EUR 1,066m; comprehensive equity EUR 16.1bn, EUR 88.14/share vs EUR 85.04 FY2023); FY2025 earnings call (comprehensive equity EUR 17.5bn; "current cash position" EUR 1.45bn, quoted at the Feb 2026 call).
Additional balance-sheet datapoints
Commentary. Under IFRS 17, comprehensive equity (shareholders' equity plus the net-of-tax CSM) is the best measure of the book. It grew from EUR 16.1bn to EUR 17.5bn in FY2025, helped by NOR and the esure-related capital increase, net of FX (TRY, CNY, INR weakness) and dividends. Solvency has been deliberately deployed: from ~218–219% in 2022–24, down to ~195% at H1 2026 after the AG step-up (EUR 1.9bn) and esure (EUR 1.51bn). Roughly +23pp has since been rebuilt through the MAHB sale. Implied post-MAHB solvency is ~218%, a simple sum not disclosed by the company. The group issued new Tier 2 and Restricted Tier 1 notes and a GBP senior note in 2025 (rating page), consistent with partial debt funding of esure and AG.
Cash flow and capital return
Sources: FY2022 press release (OFCG EUR 1,172m); FY2024 call (dividends received EUR 805m, +12% YoY, from which FY2023 ≈ EUR 719m is derived); FY2025 press release and call (cash upstream EUR 949m, +18%; HFCF EUR 774m); Aug 2024 announcement of a EUR 200m buyback. FY2026 cash upstream guidance is above EUR 1.4bn, +49% (H1 2026 release), up from EUR 1.2bn guided in February 2026.
Commentary. For Ageas, the relevant cash metric is upstream from operating entities to the holding. Upstream has compounded at ~7% p.a. over 2017–2025 (corporate presentation, 8 Oct 2026). It will step up sharply in 2026 to above EUR 1.4bn, helped by 100% AG ownership, esure and higher Asia remittances. The 2025–27 HFCF target has been raised twice, from above EUR 2.2bn to above EUR 2.3bn and then above EUR 2.6bn. The shareholder remuneration target has risen to above EUR 2.2bn.
Ratios
Payout is computed as DPS / NOR EPS. The FY2025 payout falls to ~43% because of the China one-off. On adjusted NOR of EUR 1,355m, the payout would be roughly 52–53%, an approximation based on the share count.
H1 2026 ROE on NOR was 15.8%. Current ratio, cash conversion cycle and EBITDA-based ratios are not applicable to an insurance balance sheet.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | What it contains | Ownership / consolidation |
|---|---|---|
Belgium | AG Insurance (Life: guaranteed and unit-linked savings, group pensions/employee benefits, health; Non-Life: motor, fire/home, liability, workers' compensation, SME) plus AG Real Estate | 75% until 28 Apr 2026, 100% thereafter; fully consolidated |
Europe | UK (Ageas UK, esure from 30 Sep 2025, AICL/Saga), Portugal (Ageas Portugal group), Türkiye (AgeSA Life & Pension, Aksigorta Non-Life — JVs with Sabancı) | UK and Portugal consolidated; Türkiye equity-accounted |
Asia | China (Taiping Life 24.9%; Taiping Pension 10% from 2026), India (Ageas Federal Life 74%; Royal Sundaram General 40%), Thailand (Muang Thai), Vietnam, Philippines, Laos, Cambodia; Malaysia/Singapore (MAHB 30.95%) until 11 Sep 2026 | Mostly non-consolidated (equity-accounted); stakes in Taiping AM (20%) and Taiping Re (25%) per Caixin, May 2024 |
Reinsurance | Ageas Re: third-party inward P&C and Life reinsurance plus internal reinsurance | Fully consolidated (part of ageas SA/NV) |
General Account | Holding company: cash, debt, legacy items (e.g., the RPN(i) liability linked to BNP Paribas Fortis CASHES), group costs | Holding |
Revenue by Segment
| Segment (EUR Mn) | FY2024 | FY2025 |
|---|---|---|
Belgium gross inflows | 5,331 | 5,615 |
Europe gross inflows | 4,163 | 4,404 |
Asia gross inflows | 8,599 | 8,699 |
Reinsurance 3rd-party inflows (derived residual) | 396 | 882 |
Group gross inflows | 18,489 | 19,600 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansRevenue by Segment by Segment NOR
| Segment NOR (EUR Mn) | FY2024 | FY2025 |
|---|---|---|
Belgium | 468 | 497 |
Europe | 203 | 241 |
Asia | 527 | 860 |
Reinsurance | 164 | 208 |
General Account (derived) | -122 | -151 |
Group Net Operating Result | 1,240 | 1,655 |
Profitability KPI
| Profitability KPI | FY2024 | FY2025 | H1 2025 | H1 2026 |
|---|---|---|---|---|
Group Non-Life combined ratio (%) | 93.3 | 92.5 | 92.1 | 95.2 |
Belgium Life guaranteed margin (bps) | — | 102 | 92 | — |
Group ROE on NOR (%) | 16.3 | 19.3 | — | 15.8 |
Business Lines
| Line (EUR Mn) | FY2022 | FY2024 | FY2025 |
|---|---|---|---|
Life gross inflows | 11,300 | 11,700 | — |
Non-Life gross inflows | 5,100 | 6,800 | — |
Life Net Operating Result | — | 909 | 1,259 |
Non-Life Net Operating Result | — | 454 | 548 |
Key Financials and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross inflows (EUR Mn) | — | 16,400 | 17,118 | 18,489 | 19,600 |
Group insurance result (EUR Mn) | — | — | — | — | 1,761 |
Net Operating Result (EUR Mn) | — | — | 1,166 | 1,240 | 1,655 |
Net Operating Result ex-China one-off (EUR Mn) | — | — | 1,166 | 1,240 | 1,355 |
Net result attributable (EUR Mn) | 845 | 1,011 | 953 | 1,118 | 1,712 |
Net Operating EPS (EUR) | — | — | 6.35 | 6.78 | 8.80 |
Gross dividend per share (EUR) | 2.75 | 3.00 | 3.25 | 3.50 | 3.75 |
Margin Analysis (%)
| Ratio (%) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Net result / gross inflows (%) | 6.2 | 5.6 | 6.0 | 8.7 |
NOR / gross inflows (%) | — | 6.8 | 6.7 | 8.4 |
Combined ratio Non-Life (%) | — | — | 93.3 | 92.5 |
Balance Sheet and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Holding cash / General Account liquid assets (EUR Mn) | — | 600 | — | 1,066 | 1,450 |
Comprehensive equity incl. CSM (EUR Mn) | — | — | — | 16,100 | 17,500 |
Comprehensive equity per share (EUR) | — | — | 85.04 | 88.14 | — |
Solvency II ratio, year-end (%) | 197 | 218 | — | — | — |
Datapoint Details
| Datapoint | Value | Source |
|---|---|---|
Solvency II ratio, H1 2024 | 219% | H1 2024 press release |
Pro-forma Solvency II ratio incl. esure and Saga (H1 2025) | 205% | H1 2025 call |
Solvency II ratio, H1 2026 | 195% | H1 2026 press release (impacted by the AG step-up, Taiping Pension, debt instruments and the Belgian sovereign downgrade) |
MAHB sale impact on Solvency II | +23pp (completed Sep 2026; guided ~25pp in Aug 2026) | Ageas release, 11 Sep 2026 |
Neutral solvency level (management) | 175% | H1 2025 call |
Contractual Service Margin, H1 2026 | EUR 11.1bn | H1 2026 press release |
Life liabilities, H1 2026 | EUR 117bn | H1 2026 press release |
Pension assets under management incl. Taiping Pension share | EUR 17.4bn | H1 2026 press release |
Enterprise value (aggregator) | EUR 21.13bn | GuruFocus |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Cash upstream from insurance entities (EUR Mn) | — | 719 | 805 | 949 |
Holding Free Cash Flow (EUR Mn) | — | — | — | 774 |
Operational free capital generation (EUR Mn) | 1,172 | — | — | — |
Share buyback announced (EUR Mn) | — | — | 200 | — |
Returns & Leverage Ratios (%)
| Ratio | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
ROE on NOR (%) | — | 16.3 | 19.3 |
Dividend payout on NOR EPS (%) | 51 | 52 | 43 |
Revenue by Region
| Region (EUR Mn) | FY2024 | FY2025 |
|---|---|---|
Belgium | 5,331 | 5,615 |
Europe excl. Belgium (UK, Portugal, Türkiye) | 4,163 | 4,404 |
Asia | 8,599 | 8,699 |
Reinsurance 3rd party (global, derived) | 396 | 882 |
Growth (%)
| Growth (%) | FY2025 vs FY2024 |
|---|---|
Belgium (reported) | 5.3 |
Europe (reported) | 5.8 |
Asia (reported) | 1.2 |
Group (constant FX) | 9.0 |
Country Overview
| Country | Metric | Period | Value | Source |
|---|---|---|---|---|
UK | Gross written premium (GBP M) | H1 2025 → H1 2026 | 726.3 → 1210 | Insurance Times, 27 Aug 2026 |
Malaysia/Singapore (MAHB) | NOR (EUR M) / remitted (EUR M) | FY2025 | 64 / 21 | Ageas, 3 Aug 2026 |
Belgium | Market share Life / Non-Life (%) | FY2025 | 28 / 17 | Ageas corporate presentation, 8 Oct 2026 |
Belgium | Combined ratio before quota share (%) | FY2025 | 90.5 | Same |
China (Taiping Pension) | Pension AUM (EUR bn, 100%) | 2023 | 71 | Ageas, May 2024 |
Price Datapoint Details
| Price datapoint (EUR unless noted) | Value | Date / source |
|---|---|---|
Latest price | 71.73 | 9 Oct 2026 (Lang & Schwarz, via ad-hoc-news) |
Price on MAHB completion day | 75.10 | 11 Sep 2026 (Trivano) |
52-week range | 55.85–75.05 | MarketScreener, Aug 2026 |
YTD 2026 change | +20.3% | MarketScreener, 21 Aug 2026 |
3-year low | 35.66 | MarketScreener |
5-year low | 33.70 | MarketScreener |
Share Price
| Metric | Oct 2021 | Oct 2022 | Oct 2023 | Oct 2024 | Oct 2025 | Jul 2026 |
|---|---|---|---|---|---|---|
AGESY price (USD) | 48.79 | 34.55 | 38.46 | 52.14 | 66.67 | 81.38 |
Valuation Snapshot
| Multiple | Value | Source / basis |
|---|---|---|
P/E (FY2025 EPS EUR 8.80 at EUR 71.73) | 8.2x | Computed |
P/E 2026e (consensus) | 9.36x | MarketScreener (Aug 2026) |
P/E 2027e (consensus) | 8.87–9.05x | MarketScreener |
P/B | 1.44–1.47x | GuruFocus |
EV / Sales 2026e | 1.13–1.15x | MarketScreener |
Dividend yield (FY2025 DPS EUR 3.75 at EUR 71.73) | 5.2% | Computed |
Dividend yield 2026e / 2027e | 5.5–5.6% / 5.9–6.0% | MarketScreener |
Capital Markets
| Item | Value | Source |
|---|---|---|
Coverage | ~25–26 analysts | Simply Wall St |
Consensus price target | ~EUR 70 (Simply Wall St); USD 79.22 for the ADR (getquin) | Discrepancy across aggregators and dates |
Notable recent actions | JPMorgan PT raised from EUR 70 to EUR 80 (5 Oct 2026); Berenberg PT raised, Buy (4 Aug 2026); AlphaValue/Baader "Add" (3 Aug 2026) | TipRanks / MT Newswires |
Last half-year EPS vs consensus | EUR 3.94 vs EUR 3.67 (H1 2026, per TipRanks data) | TipRanks |
Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Interim DPS (EUR) | — | — | 1.50 | 1.50 | 1.50 |
Final DPS (EUR) | — | — | 1.75 | 2.00 | 2.25 |
Total gross DPS (EUR) | 2.75 | 3.00 | 3.25 | 3.50 | 3.75 |
Capital Programmes
| Programme | Size (EUR Mn) | Announced | Status |
|---|---|---|---|
Share buyback | 200 | Aug 2024 (H1 2024 results) | — |
New buyback programmes 2025–26 | Not announced | — | Capital prioritised for esure and AG. MAHB proceeds could fund future buybacks — unconfirmed. |
Group Entities
| Entity | S&P | Moody's | Fitch |
|---|---|---|---|
ageas SA/NV (IFS) | A+ / Stable (17 Apr 2025) | A1 / Stable (16 Oct 2024) | AA- / Stable (affirmed 14 Oct 2026) |
AG Insurance (IFS) | A+ / Stable | A1 / Stable | AA- / Stable (affirmed 14 Oct 2026) |
Ageas Insurance Ltd (UK) (IFS) | A+ / Stable | NR | AA- / Stable (affirmed 14 Oct 2026) |
Ageas Insurance International | NR | NR | A+ / Stable (Oct 2025) |
Issuer Details
| Issuer | Instrument | S&P | Moody's | Fitch |
|---|---|---|---|---|
Ageasfinlux SA | FRESH grandfathered Restricted Tier 1 (2002), perpetual | A- | Baa2 | BBB |
AG Insurance | Fixed-rate reset dated subordinated Tier 2 (2015, due 2047) | A- | NR | A- |
ageas SA/NV | Subordinated fixed-to-floating Tier 2 (2019) | A- | NR | A- |
ageas SA/NV | Perpetual RT1, fixed-rate resettable, temporary write-down (2019) | BBB+ | NR | BBB+ |
ageas SA/NV | Subordinated fixed-to-floating Tier 2 (2020, due Nov 2051) | A- | NR | A- |
ageas SA/NV | Subordinated fixed-to-floating Tier 2 (2025) | A- | NR | A- |
ageas SA/NV | Perpetual RT1 (2025) | BBB+ | NR | BBB+ |
ageas SA/NV | GBP Senior Fixed Rate Notes (2025) | A+ | A1 | NR |
Analyst Conclusions
Management guidance (latest)
| Item | Guidance |
|---|---|
| FY2026 Net Operating Result | >EUR 1.95bn, incl. ~EUR 450m MAHB gain (realised EUR 464m), less ~EUR 30m of lost MAHB contribution, assuming ~3pp weather on the combined ratio |
| FY2026 cash upstream | >EUR 1.4bn (+49%) |
| FY2026 interim DPS | EUR 1.50 (December 2026) |
| 2025–27 average EPS growth | 6–8% |
| 2027 EPS | EUR 8.00–8.50, upper end expected |
| 2025–27 HFCF | >EUR 2.6bn |
| 2025–27 shareholder remuneration | >EUR 2.2bn; DPS +6% p.a. |
| Discounted combined ratio 2027 | ~92% (excl. exceptional weather) |
| UK synergies | >GBP 130m p.a.; full run-rate from 2028 |
Consensus growth expectations. Consensus P/E of 9.36x (2026e) and 8.87–9.05x (2027e) implies EPS growth of about 3–5% from 2026 to 2027 on a reported basis. 2026 is inflated by the MAHB gain, so the underlying growth expectation is higher.
Bull case
-
Cash inflection. Upstream jumps from EUR 949m to above EUR 1.4bn in 2026. With 100% of AG, esure synergies arriving in 2027–28 and Asia remittances improving, cumulative HFCF above EUR 2.6bn could support dividend growth above 6% and/or renewed buybacks funded by the ~EUR 1.1bn MAHB proceeds.
-
Underlying earnings compounding. Ex-one-offs, NOR grew about 9% in FY2025 and is guided at roughly EUR 1.5bn+ for 2026 despite EUR 180m of H1 weather. The 2027 EPS target sits at the upper end of EUR 8.00–8.50. On a ~EUR 72 share price, that is under 9x 2027 earnings with a ~5.5% yield.
-
Value-realisation optionality. The MAHB sale at ~2x book and ~15x earnings shows the hidden value of Asian minorities carried on balance sheet. Similar dynamics (Taiping, India, Thailand) and a strategic reference shareholder (BNP) provide a valuation floor and potential re-rating.
Bear case
-
Earnings quality. Headline NOR is flattered by one-offs: EUR 300m China tax in 2025 and EUR 464m disposal gain in 2026. Asia, the largest NOR segment (EUR 860m in FY2025), converts poorly into cash, and China's rate and regulatory environment remains volatile.
-
UK integration and cycle. esure was bought near the peak of UK motor pricing. With the market softening (management, 2025), synergy delivery may only offset margin compression. Full financial contribution is not expected before 2028.
-
Capital consumption and concentration. Solvency fell from ~219% to 195% before the MAHB rebuild. Weather and Belgian sovereign spread risk are concentrated, and BNP Paribas's ~24.1% stake may cap takeover premia while constraining strategic independence.
Key catalysts and monitorables (next 12 months)
| Timing | Catalyst / monitorable |
|---|---|
| Dec 2026 | Payment of the EUR 1.50 interim dividend |
| Q4 2026 – Q1 2027 | Decision on deploying MAHB proceeds (M&A vs buyback) |
| Jan 2027 | Reinsurance renewals (Ageas Re pricing and volume) |
| ~24 Feb 2027 | FY2026 results: delivery vs >EUR 1.95bn NOR; FY2026 DPS (EUR 3.75 × 1.06 ≈ EUR 3.98 implied); FY2027 guidance |
| 2,027 | esure integration milestones and synergy tracking (>GBP 130m) |
| 1 Jan 2027 | Start of the renewed 15-year BNP Paribas Fortis bancassurance agreement |
| Within ~3 years of Mar 2026 | Possible exercise of the Taiping Pension step-up to 24.99% |
| Ongoing | Belgian and Portuguese weather; UK motor pricing; Chinese discount rates and tax; Belgian sovereign rating; any BNP Paribas stake movements |
| Late 2027 | Next strategic cycle (post-Elevate27) — likely a Capital Markets Day |
Concluding analyst verdict
Ageas enters late 2026 materially reshaped. In eighteen months, management bought out BNP Paribas Fortis's 25% of AG Insurance, acquired esure and Saga's underwriter to build a top-three UK personal-lines platform, took a foothold in Chinese pensions, and sold its Malaysian minority at roughly twice book. Each move pushes the group from a holding of minority partnerships toward an owner-operator of consolidated, remittable earnings. That shift is the core of the investment case, and it is now visible in the numbers. Cash upstream is guided up 49% to above EUR 1.4bn in 2026, and the cumulative 2025–27 Holding Free Cash Flow target has risen to above EUR 2.6bn from above EUR 2.2bn at launch.
Operating fundamentals are sound. The Non-Life combined ratio held at 92–93% through 2024–25 and the Belgian Life guaranteed margin is above 100 bps, while the AA- Fitch rating was reaffirmed this month. The caveats are real. Reported profit in 2025 and 2026 is flattered by a EUR 300m China tax benefit and a EUR 464m disposal gain. Asia still generates far more accounting profit than cash, and UK motor is entering a softer phase just as esure integration peaks. Weather is now a recurring rather than exceptional drag.
On roughly 8–9x forward earnings and a dividend yield of about 5.5%, with DPS growth contractually framed at 6% a year, the market prices Ageas as a low-growth income stock. That stance seems to under-credit both the cash inflection and the latent value in its Asian stakes. The MAHB sale crystallised that value at ~15x earnings.
-
clean delivery of UK synergies;
-
disciplined redeployment of the MAHB proceeds;
-
continued conversion of Asian earnings into holding cash.
BNP Paribas's near-25% stake is best viewed as a stabilising anchor rather than an imminent bid catalyst.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | In role since | Background / prior roles | Education | Age |
|---|---|---|---|---|---|
Hans De Cuyper | CEO, Executive Director | Oct 2020 | CEO AG Insurance; earlier CEO and CFO of Etiqa (Maybank Ageas JV), Malaysia | — | 57 (MarketScreener) |
Wim Guilliams | CFO, Executive Director | 1 Jun 2023 (Deputy CFO from 1 Jan 2023) | CFO AG Insurance from 2015; previously executive and board roles at KBC Group (Belgium, CEE) and ING Insurance Belgium; led group IFRS 17 implementation | Master in Applied Economic Sciences (KU Leuven, 1994); post-graduate in financial risk management (Saint-Louis Brussels); MBA in Financial Services & Insurance | Born 1973 |
Christophe Vandeweghe | CRO, Executive Director | 1 Jun 2024 | CFO Ageas Portugal; CRO Continental Europe | — | — |
Heidi Delobelle | Managing Director Belgium (CEO AG Insurance) | 1 Jun 2024 (ExCo) | CEO AG Insurance | — | — |
Ben Coumans | Managing Director Europe (UK, Portugal, Türkiye) | 1 Jun 2024 | Group Director Strategy and M&A; succeeded Antonio Cano | — | — |
Filip Coremans | Managing Director Asia | — | Long-standing Ageas executive | — | — |
Emmanuel Van Grimbergen | MD Reinsurance & Investments | 1 Jun 2024 | Group CRO before 2024 | — | — |
Karolien Gielen | Managing Director Business Development | 2024 | — | — | — |
“—” = not publicly disclosed.
Board of Directors by Director
| Director | Role | Committee leadership | Independence |
|---|---|---|---|
Bart De Smet | Chairman (since 2020) | Chair, Nomination & Corporate Governance Committee | — |
Yvonne Lang Ketterer | Vice-Chair | Chair, Risk & Capital Committee | Independent |
Xavier de Walque | Director | Chair, Audit Committee (per Ageas leadership page) | Independent |
Katleen Vandeweyer | Director | Chair, Remuneration Committee | Independent |
Alicia García Herrero | Director | — | Independent |
Carolin Gabor | Director | — | Independent |
Jean-Michel Chatagny | Director | — | Independent |
Françoise Lefèvre | Director | — | Independent (presumed) |
Sonali Chandmal | Director | — | Independent (presumed) |
Renaud Dumora | Director (appointed AGM 20 May 2026) | — | Non-independent; BNP Paribas nominee under the shareholder agreement |
Hans De Cuyper | CEO | — | Executive |
Wim Guilliams | CFO | — | Executive |
Christophe Vandeweghe | CRO | — | Executive |
Executive Leadership Team
| Name | Role | Total compensation (EUR) |
|---|---|---|
Hans De Cuyper | CEO | 2,350,000 |
Wim Guilliams | CFO | 1,350,000 |
Christophe Vandeweghe | CRO | 1,270,000 |
Bart De Smet | Non-executive Chair | 185,000 |
Independent non-executives (range) | Directors | 92000–120500 |
Board & Management Changes
| Date | Change |
|---|---|
1 Jan 2023 / 1 Jun 2023 | Wim Guilliams Deputy CFO, then CFO; Christophe Boizard retires after 11+ years |
15 May 2024 AGM / 1 Jun 2024 | ExCo enlarged to eight; Vandeweghe CRO; Van Grimbergen MD Reinsurance & Investments; Delobelle MD Belgium; Coumans MD Europe (replacing Antonio Cano); Gielen joins |
30 Sep 2025 | esure leadership change on completion |
20 May 2026 AGM | Renaud Dumora (BNP Paribas nominee) appointed non-executive director |
Major Shareholders
| Holder | Stake (% of shares) | Notes / date |
|---|---|---|
BNP Paribas Cardif (BNP Paribas Group) | 22.5 | After the EUR 1.1bn capital contribution at EUR 60/share; crossed 20% on 28 Apr 2026 |
BNP Paribas Fortis (BNP Group) | 1.62 | 3,473,271 shares pledged to CASHES holders; voting suspended |
Belgian State (SFPI/FPIM) | ~6.0 | Diluted from 6.3% by the BNP capital increase (Test-Aankoop, Dec 2025) |
Free float | ~65.3 | MarketScreener |
Insiders (directors and officers) | <1 (individual holdings not disclosed in sources reviewed) | — |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | — |
|---|---|---|
Belgium | KBC Insurance (KBC Group) | Bancassurance rival; KBC's integrated bank-insurer model competes directly with the AG–BNP Paribas Fortis channel |
Belgium | Belfius Insurance | State-owned bank-insurer; strong in retail and public sector |
Belgium | Ethias | Mutual-origin insurer; strong in public sector and retail |
Belgium | AXA Belgium | Major broker-channel competitor in P&C |
Belgium | Allianz Benelux; NN Belgium; P&V/Vivium; Baloise Belgium | Broker and life competitors; AG remains #1 with 28% Life / 17% Non-Life share |
UK personal lines | Aviva (incl. Direct Line after its 2025 acquisition) | Largest UK personal-lines player; Ageas competed for Direct Line in 2024 |
UK personal lines | Admiral Group | Leading PCW/direct motor insurer; benchmark for digital efficiency |
UK personal lines | Hastings Direct | PCW-focused motor/home competitor |
UK personal lines | LV= / Allianz UK; AXA UK; Zurich UK; RSA (Intact) | Broker and affinity competition |
Portugal | Fidelidade; Generali Tranquilidade; Allianz Portugal | Ageas is #2 by premiums (post-2016) |
Türkiye | Allianz Sigorta; Anadolu Sigorta; other bank-owned insurers | — |
China | Ping An; China Life; CPIC; New China Life | Taiping Life is a significant but non-top-3 player |
India | LIC; SBI Life; HDFC Life; ICICI Prudential | Ageas Federal Life is a small private player targeting 3x growth |
Reinsurance | Munich Re; Swiss Re; Hannover Re; SCOR | Ageas Re is a sub-scale niche entrant |
European multi-line peers (investor benchmark) | NN Group; ASR Nederland; Aegon; Baloise/Helvetia; Generali; AXA | Valuation and capital-return comparables |
Competitor Detail
| Metric (FY2025) | Ageas |
|---|---|
Gross inflows / premiums (EUR Bn) | 19.6 |
Top-line growth, constant FX (%) | 9 |
Operating ROE (%) | 19.3 |
Non-Life combined ratio (%) | 92.5 |
Forward P/E 2026e (x) | 9.4 |
Recent Developments
*Layoffs / hiring. esure/Ageas UK integration synergies above GBP 130m imply cost and headcount actions in the UK, but specifics are not publicly disclosed.
*Litigation and regulatory actions.



